04/27/22 Health Advisory: CDC Treatment Updates and ACIP discusses second COVID-19 booster dose eligibility

Ariel shot of someone taking notes or completing paperwork

Requested actions

    • Be aware, on April 20, 2022, CDC’s Advisory Committee on Immunization Practices (ACIP) discussed those who are eligible to get a second booster dose of COVID-19 vaccine (i.e., 50 years or older; 12 years or older and moderately to severely immunocompromised; got Johnson & Johnson vaccine for their primary series and first booster). It is especially important for these people to get a second booster dose if they:
      • Have certain medical conditions that increase the risk of severe disease.
      • Are moderately or severely immunocompromised.
      • Live with a person who is immunocompromised, at increased risk of severe disease, or cannot get COVID-19 vaccine because of age or contraindication.
      • Are at increased risk of COVID-19 exposure because of occupational, institutional or other activities.
      • Live or work in an area with medium or high COVID-19 community level.
  • Connect patients to free COVID-19 testing locations to help them get COVID-19 medication for free, no insurance needed.


Early outpatient treatment of COVID-19 can prevent serious, potentially life-threatening illness and reduce burden on the healthcare system. CDC issued a HAN advisory on Dec. 31, 2021 to address using therapeutics in the outpatient setting for people with COVID-19. At that time, Omicron cases were rapidly increasing in the United States and some therapeutics were in short supply. Now antivirals for COVID-19 are widely available and accessible by prescription at pharmacies and Test-to-Treat locations nationwide.

Data from CDC (highlighted in a Feb. 13, 2021 CDC Infectious Diseases Society of America COVID-19 clinical call) and Food and Drug Administration (FDA) suggest use of systemic corticosteroids and antibiotics to treat outpatients with COVID-19 is increasing. However, these drugs can cause harm and provide no demonstrated benefit in patients with COVID-19 with no supplemental oxygen requirement or bacterial coinfection. Systemic corticosteroid short courses are associated with adverse events like hyperglycemia, gastrointestinal bleeding, psychosis, infection and long-term effects.

NIH provides COVID-19 treatment guidelines. The guidelines panel provides treatment options and recommends against using systemic corticosteroids to treat patients with mild to moderate COVID-19 who do not require supplemental oxygen. Patients who receive dexamethasone or other corticosteroids for other indications should continue therapy as directed by their healthcare provider. NIH recommends systemic corticosteroids for hospitalized patients with COVID-19 who require supplemental oxygen or higher-level respiratory support.

The guidelines panel also recommends against using antibacterial therapy for COVID-19 in the absence of another indication. Antibacterial drugs have no benefit in treating viral infections and can cause harm.

More information

COVID-19 vaccine information

COVID-19 testing

COVID-19 test processing

Labs report varying amounts of time to process COVID-19 tests. To support faster turnaround, we encourage providers to use in-state labs. The table below shows COVID-19 test processing times for in-state private labs.

Lab Time to process test Tests processed daily
FidaLab 24 hours 300
Kaiser 24–48 hours 3,000
LabCorp 24–48 hours Unknown
Northwest Pathology 12–24 hours 3,000
Quest 24–48 hours 700
UW Virology 24–72 hours 5,000–7,000
Atlas Genomic 24–48 hours 10,000

COVID-19 therapies

Department of Health and Human Services (HHS) allocates monoclonal antibodies and oral antivirals to each state. DOH distributes doses to enrolled providers. Providers must enroll in Healthcare Partner Ordering Portal (HPoP) to manage COVID-19 therapies. Email mcm@doh.wa.gov for support enrolling.

Once enrolled, to request a supply of monoclonal antibodies or therapeutics, complete a smart sheet. Providers can now order treatments directly through HPoP.

Additional information

COVID-19 prevention

Share with patients:

Immediately report COVID-19

Providers must fax positive lab results with demographic information to 509-381-3526.

Contacting the Health Department

Questions? Contact Yakima Health District at (509) 575-4040 or (800) 535-5016.

Additional resources